|
|
| 24.66 Data as of Dec 10 |  -0.41 / -1.64%Today’s Change | 14.43 Today|||52-Week Range 28.42 | +67.64% Year-to-Date |
| Theravance (THRX) in Focus: Stock Adds 5.0% - Tale of the Tape Dec 09 / Zacks.com | Positive Data on ChemoCentryx Candidate - Analyst Blog Dec 05 / Zacks.com |
| Oculus Gains on Scar Product Approval - Analyst Blog Dec 05 / Zacks.com | Cytokinetics Progresses with Tirasemtiv - Analyst Blog Dec 05 / Zacks.com |
| MYGN Unveils Prolaris Study Results - Analyst Blog Dec 05 / Zacks.com | Affymetrix Remains Outperform - Analyst Blog Dec 04 / Zacks.com |
| BioMarin Seeks Canadian Approval - Analyst Blog Dec 05 / Zacks.com | MYGN Battles Odds, Shares Fall - Analyst Blog Dec 04 / Zacks.com |
| AMBI Plunges on Disappointing FDA News - Analyst Blog Dec 05 / Zacks.com | Zacks #1 Rank Additions for Wednesday - Tale of the Tape Dec 04 / Zacks.com |
| Previous close | 25.07 |
| Today’s open | 24.97 |
| Day’s range | -- - -- |
| Volume | 90,056 |
| Average volume (3 months) | 132,468 |
| Market cap | $544.9M |
| Dividend yield | -- |
| Earnings growth (last year) | +78.57% |
| Earnings growth (this year) | +58.06% |
| Earnings growth (next 5 years) | +35.00% |
| Revenue growth (last year) | +39.39% |
| P/E ratio | NM |
| Price/Sales | 3.69 |
| Price/Book | 3.12 |
| Today’s change | Today’s % change | |
|---|---|---|
| TRIBTrinity Biotech PLC | -0.41 | -1.72% |
| ALRPRBAlere Inc | +4.10 | +1.48% |
| DNDNDendreon Corp | -0.04 | -1.33% |
| GERNGeron Corp | -0.37 | -6.70% |
| Next reporting date | February 28, 2014 |
| EPS forecast (this quarter) | -$0.07 |
| Annual revenue (last year) | $85.4M |
| Annual profit (last year) | -$16.8M |
| Net profit margin | -19.62% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director William K. Heiden |
Chief Operating Officer & Executive Vice President Frank E. Thomas |
Corporate headquarters Lexington, Massachusetts |
.
